ArticleJournal of cachexia, sarcopenia and muscle2013
Butyrylcholinesterase as a prognostic marker: a review of the literature.
Article in Journal of cachexia, sarcopenia and muscle, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed, 2 syntheses or guidelines pooled it, 289 citations in OpenAlex.
- Butyrylcholinesterase Activity as a Mortality Marker in ICU Patients: An Individual Participant Data Meta-Analysis.Critical care explorations · 2026Pooled it
- MRI-based radiomics for predicting pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Dynamic Changes in Serum Choline Acetyltransferase and Acetylcholinesterase in Septic versus Non-Septic ICU Patients: A Prospective Exploratory Study.Journal of inflammation research · 2026Trial
- Plasma proteomics reveals markers of metabolic stress in HIV infected children with severe acute malnutrition.Scientific reports · 2020Trial
- Changes in Cholinesterase Activity in Blood of Adolescent with Metabolic Syndrome after Supplementation with Extract fromBioMed research international · 2018Trial
- Serum cholinesterase as a prognostic marker in respiratory critical illness: a narrative review.Wiener klinische Wochenschrift · 2026Review
- Adaptive variation in butyrylcholinesterase-influenced lipid metabolism during horse domestication.Cell reports · 2026Article
- Starch as a Polymer-Based Medium Modifier to Analyze Enzyme Activity under Conditions Close to Intracellular Media: Butyrylcholinesterase as a Model Enzyme.Doklady. Biochemistry and biophysics · 2026Article
- Association of serum butyrylcholinesterase with concurrent dry-weight change in maintenance hemodialysis: a retrospective longitudinal study.BMC nephrology · 2026Observational
- Article
- Evaluation of oxidative stress in ill neonatal foals: a preliminary study.Journal of veterinary internal medicine · 2026Article
- Mendelian randomization linking metabolites with enzymes reveals pathway regulation and therapeutic avenues.American journal of human genetics · 2026Article
- Genetic and Epigenetic Mechanisms in Serrated Adenocarcinomas and Classical Colorectal Carcinomas: An In Silico Study.Current issues in molecular biology · 2026Article
- Low serum pseudocholinesterase levels are associated with mortality in patients with hepatocellular carcinoma.Hepatology communications · 2026Article
- Development and validation of an interpretable machine learning model for early prediction of postoperative atrial fibrillation following on-pump cardiac surgery.Frontiers in surgery · 2026Article
- Effect of Preweaning Socialization on Postweaning Biomarkers of Stress, Inflammation, Immunity and Metabolism in Saliva and Serum of Iberian Piglets.Animals : an open access journal from MDPI · 2025Article
- Machine Learning Prediction of Poor Flexion-Extension Outcome After Open Elbow Arthrolysis: Identifying Individual Predisposition Using Clinical and Laboratory Indicators.Orthopaedic journal of sports medicine · 2025Article
- Significance of Serum Cholinesterase as a Prognostic Marker in Patients with Non-dialysis-dependent Chronic Kidney Disease.Internal medicine (Tokyo, Japan) · 2025Article
- The Selectivity of Butyrylcholinesterase Inhibitors Revisited.Molecules (Basel, Switzerland) · 2025Review
- Development and validation of a gene signature for gastric cancer prognosis based on propionate metabolism.Translational cancer research · 2025Article
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundButyrylcholinesterase (BChE) is an α-glycoprotein synthesized in the liver. Its serum level decreases in many clinical conditions such as acute and chronic liver damage, inflammation, injury and infections, and malnutrition. METHODS AND
resultsThis review collects the main evidence on the emerging role of butyrylcholinesterase as a prognostic marker of liver and nonliver diseases as well as a marker of protein-energy malnutrition and obesity. In fact, serum concentrations and BChE activity seem to accurately reflect the availability of amino acidic substrates and/or derangement in protein synthesis due to hepatocellular damage. In cancer, with or without liver impairment, serum BChE levels serve as an accurate functional and prognostic indicator, useful for monitoring clinical and therapeutic interventions according to patients' prognosis. In the absence of inflammation, BChE could also serve as an index of the effectiveness of nutritional support.
conclusionsSerum BChE assessment should be included in routine clinical diagnostic procedures to evaluate patient clinical conditions, in particular in cases of inflammation and/or protein-energy malnutrition.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.